Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL
Pierre‐Yves Dumas, Cécile Naudin, Severine Martin‐Lannerée, et al.
Haematologica (2019) Vol. 104, Iss. 10, pp. 2017-2027
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Yang Yang, Shuo Li, Yujiao Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 143
A review of FLT3 inhibitors in acute myeloid leukemia
Jennifer Zhao, Sonal Agarwal, Hiba Ahmad, et al.
Blood Reviews (2021) Vol. 52, pp. 100905-100905
Open Access | Times Cited: 122
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis inFLT3-Mutant Leukemia
Marie Sabatier, Rudy Birsen, Laura Lauture, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1720-1747
Open Access | Times Cited: 46
FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance
Zhijie Wang, Jiongheng Cai, Jie Cheng, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 6, pp. 2878-2900
Closed Access | Times Cited: 64
Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
Agnete S.T. Engelsen, Maria L. Lotsberg, Raefa Abou Khouzam, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy
Martina Ruglioni, Stefania Crucitta, Giovanna Irene Luculli, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104424-104424
Open Access | Times Cited: 12
Cytokine-mediated CAR T therapy resistance in AML
Anand S. Bhagwat, Leonel Torres, Olga Shestova, et al.
Nature Medicine (2024)
Closed Access | Times Cited: 9
Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers
Marie Brachet‐Botineau, Marion Polomski, Heidi A. Neubauer, et al.
Cancers (2020) Vol. 12, Iss. 1, pp. 240-240
Open Access | Times Cited: 66
Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Motoki Eguchi, Yosuke Minami, Ayumi Kuzume, et al.
Biomedicines (2020) Vol. 8, Iss. 8, pp. 245-245
Open Access | Times Cited: 56
Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
Sebastian Scholl, Maximilian Fleischmann, Ulf Schnetzke, et al.
Cells (2020) Vol. 9, Iss. 11, pp. 2493-2493
Open Access | Times Cited: 55
TAM Receptor Inhibition–Implications for Cancer and the Immune System
Pia Aehnlich, Richard Powell, Marlies J. W. Peeters, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1195-1195
Open Access | Times Cited: 55
Pharmacological Effects of Polyphenol Phytochemicals on the JAK-STAT Signaling Pathway
Qianqian Yin, Longyun Wang, Haiyang Yu, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 54
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development
Yiyi Yao, Fenglin Li, Jiansong Huang, et al.
Experimental Hematology and Oncology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 51
Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
Stephen Lam, Anskar Y.H. Leung
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 4, pp. 1537-1537
Open Access | Times Cited: 47
Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2
Ping Liu, Dan Ma, Ping Wang, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 34
Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
Yvyin Zhang, Peihong Wang, Yang Wang, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 13
Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
Solène Fernandez, Vanessa Desplat, Arnaud Villacreces, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 14, pp. 3429-3429
Open Access | Times Cited: 39
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia
Sean M. Post, Huaxian Ma, Prerna Malaney, et al.
Haematologica (2021) Vol. 107, Iss. 6, pp. 1311-1322
Open Access | Times Cited: 27
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
Pierre‐Yves Dumas, Emmanuel Raffoux, Emilie Bérard, et al.
Leukemia (2022) Vol. 37, Iss. 1, pp. 91-101
Open Access | Times Cited: 20
Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies
Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, et al.
European Journal Of Haematology (2025)
Open Access
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial
Sonja Loges, Michael Heuser, Jörg Chromik, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Targeting FLT3 for treating diseases: FLT3 inhibitors
Qingfeng Rong, Yu Lu, Wen Zhang, et al.
Drug Discovery Today (2025), pp. 104367-104367
Closed Access
Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome
David G. J. Cucchi, Richard W.J. Groen, Jeroen J.W.M. Janssen, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100730-100730
Open Access | Times Cited: 31
<p>Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date</p>
Luke B. Fletcher, Sunil K. Joshi, Elie Traer
Cancer Management and Research (2020) Vol. Volume 12, pp. 151-163
Open Access | Times Cited: 30
Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia
Pierre‐Yves Dumas, Arnaud Villacreces, Amélie V. Guitart, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 21, pp. 6012-6025
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top